These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 26919288)

  • 1. Antibody Persistence in Adults Two Years after Vaccination with an H1N1 2009 Pandemic Influenza Virus-Like Particle Vaccine.
    Valero-Pacheco N; Pérez-Toledo M; Villasís-Keever MÁ; Núñez-Valencia A; Boscó-Gárate I; Lozano-Dubernard B; Lara-Puente H; Espitia C; Alpuche-Aranda C; Bonifaz LC; Arriaga-Pizano L; Pastelin-Palacios R; Isibasi A; López-Macías C
    PLoS One; 2016; 11(2):e0150146. PubMed ID: 26919288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical Outcomes in Women Who Became Pregnant after Vaccination with a Virus-Like Particle Experimental Vaccine against Influenza A (H1N1) 2009 Virus Tested during 2009 Pandemic Outbreak.
    Cérbulo-Vázquez A; Arriaga-Pizano L; Cruz-Cureño G; Boscó-Gárate I; Ferat-Osorio E; Pastelin-Palacios R; Figueroa-Damian R; Castro-Eguiluz D; Mancilla-Ramirez J; Isibasi A; López-Macías C
    Viruses; 2019 Sep; 11(9):. PubMed ID: 31533277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs.
    Pyo HM; Masic A; Woldeab N; Embury-Hyatt C; Lin L; Shin YK; Song JY; Babiuk S; Zhou Y
    Vaccine; 2012 Feb; 30(7):1297-304. PubMed ID: 22207090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
    Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
    Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virus-like particle (VLP)-based vaccines for pandemic influenza: performance of a VLP vaccine during the 2009 influenza pandemic.
    López-Macías C
    Hum Vaccin Immunother; 2012 Mar; 8(3):411-4. PubMed ID: 22330956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of neutralizing antibody and cell-mediated immune responses to pandemic H1N1 2009 influenza virus before and after H1N1 2009 influenza vaccination of elderly subjects and healthcare workers.
    Hsu JP; Phoon MC; Koh GC; Chen MI; Lee VJ; Wu Y; Xie ML; Cheong A; Leo YS; Chow VT
    Int J Infect Dis; 2012 Aug; 16(8):e621-7. PubMed ID: 22704721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico.
    López-Macías C; Ferat-Osorio E; Tenorio-Calvo A; Isibasi A; Talavera J; Arteaga-Ruiz O; Arriaga-Pizano L; Hickman SP; Allende M; Lenhard K; Pincus S; Connolly K; Raghunandan R; Smith G; Glenn G
    Vaccine; 2011 Oct; 29(44):7826-34. PubMed ID: 21816199
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E; Boschini A; Amendola A; Poletti R; Anselmi G; Begnini M; Ranghiero A; Cecconi G; Zanetti AR
    Vaccine; 2011 Nov; 29(49):9209-13. PubMed ID: 21974995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1).
    Matassov D; Cupo A; Galarza JM
    Viral Immunol; 2007 Sep; 20(3):441-52. PubMed ID: 17931114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.
    Hancock K; Veguilla V; Lu X; Zhong W; Butler EN; Sun H; Liu F; Dong L; DeVos JR; Gargiullo PM; Brammer TL; Cox NJ; Tumpey TM; Katz JM
    N Engl J Med; 2009 Nov; 361(20):1945-52. PubMed ID: 19745214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
    Yang JR; Chen CY; Kuo CY; Cheng CY; Lee MS; Cheng MC; Yang YC; Wu CY; Wu HS; Liu MT; Hsiao PW
    Antiviral Res; 2016 Feb; 126():8-17. PubMed ID: 26593980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro.
    Hendin HE; Pillet S; Lara AN; Wu CY; Charland N; Landry N; Ward BJ
    Vaccine; 2017 May; 35(19):2592-2599. PubMed ID: 28389100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine.
    Chao DY; Cheng KF; Hsieh YH; Li TC; Wu TN; Chen CY; Tsai CA; Chen JH; Chiu HT; Lu JJ; Su MC; Liao YH;
    Vaccine; 2011 Jan; 29(4):617-23. PubMed ID: 21095255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers.
    Low JG; Lee LS; Ooi EE; Ethirajulu K; Yeo P; Matter A; Connolly JE; Skibinski DA; Saudan P; Bachmann M; Hanson BJ; Lu Q; Maurer-Stroh S; Lim S; Novotny-Diermayr V
    Vaccine; 2014 Sep; 32(39):5041-8. PubMed ID: 25045806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved serological response to H1N1 monovalent vaccine associated with viral suppression among HIV-1-infected patients during the 2009 influenza (H1N1) pandemic in the Southern Hemisphere.
    Maruszak H; Jeganathan S; Smith DE; Robertson P; Barnes T; Furner V
    HIV Med; 2012 Jul; 13(6):352-7. PubMed ID: 22296264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.
    Cramer J; Mac T; Hogan B; Stauga S; Eberhardt S; Wichmann O; Mertens T; Burchard G
    Euro Surveill; 2012 Jan; 17(2):. PubMed ID: 22264864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.